Is Rheumatology Entering the Multiomics Era?
The 52nd Congress of the Spanish Rheumatology Society emphasized the importance of precision medicine in rheumatology, particularly through the use of multiomics and biomarkers. Experts believe that these advancements will lead to more personalized treatment strategies for patients with rheumatic diseases. The integration of various biological systems is seen as crucial for improving patient outcomes and tailoring therapies effectively.
- ▪The Congress highlighted a shift toward precision medicine in rheumatology.
- ▪Experts discussed the role of multiomics and biomarkers in developing personalized treatment strategies.
- ▪Advances in fibroblast research are expected to influence future therapeutic targets in medicine.
Opening excerpt (first ~120 words) tap to expand
The 52nd Congress of the Spanish Rheumatology Society (SER) in Bilbao, Spain, highlighted a shift toward precision medicine in rheumatology, with experts pointing to multiomics, biomarkers, and targeted therapies as key tools expected to shape more personalized treatment strategies and future clinical practice. Natividad Oreiro Villar, MD, PhD, from the Rheumatology Department at the University Hospital Complex of A Coruña, A Coruña, Spain, said, “We need to bring rheumatology closer to personalized medicine.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
